{
  "schemaVersion": 1,
  "id": "research-342",
  "slug": "342-why-a-releasing-signal-produced-different-growth-hormone-responses-after-radiation",
  "title": "Why a releasing signal produced different growth hormone responses after radiation",
  "catalogLabel": "Sermorelin",
  "productCollection": "https://heritagebiolabs.com/research-library/products/sermorelin",
  "productHandles": [
    "sermorelin-631",
    "sermorelin-485",
    "sermorelin-633"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/sermorelin-631",
    "https://heritagebiolabs.com/product/sermorelin-485",
    "https://heritagebiolabs.com/product/sermorelin-633"
  ],
  "readingFocus": "Mechanisms & biology",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 269,
  "sourceYears": [
    1999,
    2013
  ],
  "paragraphs": [
    "Short amino-acid chains joined by peptide bonds can signal to glands. Sermorelin is the amidated first 29 residues of growth hormone–releasing hormone (GHRH), prepared as a synthetic peptide. An older human study examined whether an experimental GHRH(1–29) signal produced the same growth hormone pattern in healthy people and people previously treated with radiation to the brain. [1]",
    "No recent primary study repeating this specific comparison was identified. The investigators studied healthy volunteers and survivors of childhood brain tumors who had received cranial radiation. They collected frequent blood samples and evaluated how continuous exposure to the 29-residue fragment affected growth hormone (GH) peaks. They also studied the effect of changing exposure to somatostatin, another peptide that restrains GH release. [1]",
    "In the healthy adults, the GHRH fragment increased the size of GH peaks while the timing of peaks remained similar. The long-term survivors had lower spontaneous GH concentrations and responses that remained smaller than those of the healthy volunteers. The authors considered several explanations, including damage to the pituitary and changes in the signals the pituitary receives. Their experiments were designed to help distinguish these possibilities, but the cause of a lower response could differ among participants. Some long-term survivors still responded to the experimental signal, although their peak levels remained well below the comparison group's levels. [1]",
    "The result describes human hormone patterns during a defined research procedure. A pituitary gland's capacity to respond is one part of the result, while the timing of signals around it is another. The experiment did not measure long-term growth or show that the peptide treats the effects of cranial radiation. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Achermann JC et al. The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals. Clinical Endocrinology (publication 1999-11).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10594518/"
    },
    {
      "number": 2,
      "citation": "U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register (publication 2013-03-04).",
      "url": "https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/342-why-a-releasing-signal-produced-different-growth-hormone-responses-after-radiation",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/342-why-a-releasing-signal-produced-different-growth-hormone-responses-after-radiation.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/342-why-a-releasing-signal-produced-different-growth-hormone-responses-after-radiation.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 069 - Sermorelin and SLU-PP-332.docx",
    "sourceArticleNumber": 342,
    "contentSha256": "2b87e165099119684cdb432150526f5b4702e6d574fa20cc2505ff19cfe40e0d",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
